Investment Initiatives, Financial Results, Investor Conferences, Dividends, and FDA Approvals - Research Report on CareFusion, Teleflex, Cooper, HeartWare, and Thoratec

NEW YORK, August 15, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting CareFusion Corporation (NYSE: CFN), Teleflex Incorporated (NYSE: TFX), The Cooper Companies Inc. (NYSE: COO), HeartWare International Inc. (NASDAQ: HTWR), and Thoratec Corp. (NASDAQ: THOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

CareFusion Corporation Research Report

On August 8, 2013, CareFusion Corp. (CareFusion) reported its Q4 FY 2013 and full-year FY 2013 (period ended June 30, 2013) financial results with Q4 FY 2013 revenue of $903 million, compared to $961 million in Q4 FY 2012. According to the Company, the decrease in revenue was attributed to an expected decline in Medical Systems revenue, which was partially offset by strong top-line growth in the Procedural Solutions segment. Net income from continuing operations increased 20.9% YoY to $110 million and GAAP diluted EPS from continuing operations grew 19.5% YoY to $0.49. For full-year FY 2013, revenue declined 1.3% YoY to $3.6 billion, while GAAP diluted EPS from continuing operations grew 8.7% YoY to $1.74. Kieran Gallahue, Chairman and CEO commented, "We made substantial progress in fiscal 2013 to advance our three-year strategic plan through simplification and investment initiatives that were focused on expanding our margins and making CareFusion a more efficient company." The Company anticipates FY 2014 revenue to grow between 1% and 4% YoY (on a constant currency basis) and adjusted diluted EPS within $2.30 to $2.40. The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/CFN]

--

Teleflex Incorporated Research Report

On July 31, 2013, Teleflex In. (Teleflex) announced that its Board of Directors has approved a quarterly cash dividend amounting to $0.34 per share of common stock which is payable on September 13, 2013 to shareholders of record on August 15, 2013. The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/TFX]

--

The Cooper Companies Inc. Research Report

On August 5, 2013, The Cooper Companies, Inc. (Cooper) reported that it will release its Q3 FY 2013 (period ended July 31, 2013) financial results on September 5, 2013, at 4:00 p.m. ET.  Cooper also informed that it will host a conference call along with live webcast at 5:00 p.m. ET to discuss the results and current corporate developments. The Company also informed that a replay of the call will be available after 2 hours post the call ends until September 12, 2013. The Full Research Report on The Cooper Companies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/COO]

--

HeartWare International Inc. Research Report

On August 8, 2013, HeartWare International, Inc. (HeartWare) reported its Q2 2013 financial results with net revenue of $50.8 million, up 75% YoY. US revenues grew substantially to $25.1 million in Q2 2013 compared to $4.2 million in Q2 2012. Net loss for the quarter totaled $12.9 million, or $0.79 loss per basic and diluted share, compared to net loss of $22.8 million, or $1.61 loss per basic and diluted share, in Q2 2012. R&D expense for the quarter increased to $24.2 million from $20 million in Q2 2012 primarily due to clinical trial costs, development costs related to advancing HeartWare's pipeline technologies, including the MVAD platform, PAL controller and a fully-implantable system, as well as other early research initiatives. Doug Godshall, President and CEO commented, "Our results for the second quarter reflect positive initial trends in the commercial launch of the HeartWare Ventricular Assist System in the U.S., following approval from the Food and Drug Administration (FDA) late last year, as well as continued strong support from our international customers." The Full Research Report on HeartWare International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/HTWR]

--

Thoratec Corp. Research Report

On July 31, 2013, Thoratec Corp. (Thoratec) reported its Q2 2013 financial results with total reported revenue of $130.5 million, up 10% YoY. GAAP net income totaled $23.2 million, or $0.40 per diluted share, compared to $20.8 million, or $0.35 per diluted share, in Q2 2012. Gary F. Burbach, President and Chief Executive Officer said, "Thoratec delivered strong results during the second quarter, supported by our leadership positions with HeartMate II and CentriMag, as well as our intense focus on driving continued growth in the global MCS market, HeartMate II unit volume increased by nine percent on a global basis, highlighted by sequential growth in the U.S. market and robust growth internationally, driven in part by our successful initial launch in Japan." The Company reiterated its 2013 revenues guidance of $490 million to $510 million. For full-year 2013, Thoratec expects GAAP net income per diluted share to be in the range of $1.23 to $1.33. The Full Research Report on Thoratec Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/THOR]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports